Lilly's phase 2 retatrutide results show the investigational molecule achieved up to 17.5% mean weight reduction
Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program
Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program
Subscribe To Our Newsletter & Stay Updated